Correction to: Management of genetically determined kidney stone disease: consensus from a panel of urologists and nephrologists

Errata.—This article was published in Volume 77, issue 1 of publishing year 2025, with a mistake in the “Conflicts of interest”, “Funding” and “Acknowledgements” sections. The correct sections are the ones included in this erratum. Conflicts of interest All researchers received financial support from Alnylam Pharmaceuticals for their involvement in the Delphi survey. Roberto Miano served as advisory board and scientific board member from Alnylam. Pietro Manuel Ferraro received consultant fees and grant/other support from Allena Pharmaceuticals, Alnylam, Amgen, AstraZeneca, Bayer, BioHealth Italia, Gilead, Novo Nordisk, Otsuka Pharmaceuticals, Rocchetta, Vifor Fresenius, and royalties as an author for UpToDate. Funding This research was conducted with the non-conditioning assistance of Alnylam Pharmaceuticals. Research and medical writing support was provided by Polistudium SRL and sponsored by Alnylam Pharmaceuticals. Acknowledgements The authors acknowledge Francesca Cappellini (Polistudium SRL, Milan, Italy), who assisted with project coordination, and Simonetta Papa, Valentina Attanasio and Aashni Shah (Polistudium SRL, Milan, Italy), who provided editorial assistance